APGE as reported
- Net Income
- −$294M
Net Income · +24% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$233M
Free Cash Flow · trailing twelve months to Q4 2025
- EPS
- −$4.34
EPS · +5.1% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$294M | +24% | Q2 2026 |
| EPS | −$4.34 | +5.1% | Q2 2026 |
| ROE | −30% | n/a | Q2 2026 |
| ROA | −28% | n/a | Q2 2026 |
| Free Cash Flow | −$233M | n/a | Q4 2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Apogee Therapeutics, Inc. (APGE) - Net IncomeNet IncomeApogee Therapeutics, Inc. (APGE)